title: Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects.
abstract: BACKGROUND
  Atorvastatin is a recently introduced statin that lowers LDL-cholesterol (LDL-C) and triglycerides more than some of the older statins.
  
  
  METHODS
  Twenty-one Japanese hyperlipidemic subjects were treated with atorvastatin (10 mg/day) for 6 weeks. Plasma lipid concentrations and pre-heparin plasma LPL mass before and after oral administration were evaluated using an open crossover trial format. LPL mass in the pre-heparin plasma was measured by a sandwich enzyme immunoassay.
  
  
  RESULTS
  Atorvastatin decreased plasma triglyceride (TG) concentration (-21%, p<0.05), as well as plasma total and LDL-cholesterol concentrations. LPL mass in the pre-heparin plasma did not change significantly by this treatment during this period. Both apolipoprotein (apo) B and E decreased considerably (-33%, p<0.001 for apo B; -29% p<0.001 for apo E), while apo A-I concentration did not change. Other clinical parameters such as body mass index, blood pressure, and fasting plasma glucose concentration of these subjects did not change during this treatment.
  
  
  CONCLUSIONS
  Atorvastatin is effective in reducing plasma TG, which did not appear to be associated with an increased LPL mass.
authors.affiliation: Department of Internal Medicine, Chibaken Saiseikai Narashino Hospital, 1-1-1 Izumicho, Narashino, Chiba, 275-8580, Japan. koba231@attglobal.net
authors.forename: J
authors.initials: J
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Maruyama
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Shinomiya
mesh_terms: D000368:Aged; D001055:Apolipoproteins B / Q000378:metabolism; D001057:Apolipoproteins E / Q000378:metabolism; D000069059:Atorvastatin; D001786:Blood Glucose / Q000378:metabolism; D018592:Cross-Over Studies; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000201:enzymology*; D008071:Lipoprotein Lipase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D001055:Apolipoproteins B; D001057:Apolipoproteins E; D001786:Blood Glucose; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014280:Triglycerides; D000069059:Atorvastatin; D008071:Lipoprotein Lipase